List of works - Daniela Pietra

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.

scientific article published on 31 May 2017

A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis

scientific article published on 10 January 2008

A novel germline JAK2 mutation in familial myeloproliferative neoplasms.

scientific article

A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications

scientific article published on 15 July 2010

Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms

scientific article published on 10 April 2013

Allelic imbalance in CALR somatic mutagenesis

scientific article published on 8 January 2015

Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2.

scientific article published on 4 August 2005

Blast phase of essential thrombocythemia: A single center study

scientific article

Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis.

scientific article

Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations

scientific article published on 19 November 2007

CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis

scientific article published on 19 February 2014

CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles

scientific article published on 8 December 2017

COLD-PCR and Innovative Microarray Substrates for Detecting and Genotyping MPL Exon 10 W515 Substitutions

scientific article published on 11 October 2012

Cerebral venous thrombosis and myeloproliferative neoplasms: Results from two large databases

scientific article published on 29 March 2014

Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria

scientific article published on 6 October 2017

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

scientific article

Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes

scientific article

Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm

scientific article published on 31 October 2011

Clinical significance of genetic aberrations in secondary acute myeloid leukemia

scientific article published on 7 August 2012

Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders

scientific article

Clinical significance of somatic mutation in unexplained blood cytopenia

scientific article

Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms

scientific article published on 26 September 2014

Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2.

scientific article

Concordance of assays designed for the quantification of JAK2V617F: a multicenter study

scientific article

Cord blood in vitro expanded CD41 cells: identification of novel components of megakaryocytopoiesis

scientific article

Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms.

scientific article

Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms

scientific article published on 01 January 2020

Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

scientific article published on 27 May 2010

Diagnosis and management of prefibrotic myelofibrosis

scientific article published on 22 June 2018

Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.

scientific article published on 9 October 2015

Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients.

scientific article

Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia

scientific article

Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene

scientific article published on 29 April 2013

Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.

scientific article

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group

scientific article published on 2 April 2016

Familial Chronic Myeloproliferative Disorders: Clinical Phenotype and Evidence of Disease Anticipation

scientific article published on 12 November 2007

Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome

scientific article published in April 2006

Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.

scientific article

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project

scientific article published on 21 September 2018

Genetic and clinical heterogeneity of ferroportin disease

scientific article published in December 2005

Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression

scientific article published on 29 April 2011

Germline RBBP6 mutations in familial myeloproliferative neoplasms.

scientific article published on 16 November 2015

Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm

scientific article published on 22 September 2011

Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia

scientific article published on 6 August 2015

Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients.

scientific article published on 25 November 2010

Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation

scientific article (publication date: 15 July 2007)

Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosis.

scientific article

JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders

scientific article published in November 2006

JAK2 (V617F) mutation in healthy individuals

scientific article published on 01 February 2007

JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms.

scientific article published on 6 May 2012

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

scientific article published on 23 December 2013

LNK mutations in familial myeloproliferative neoplasms.

scientific article published on 23 May 2016

Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes

scientific article

Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis

scientific article published on 19 August 2009

Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations

scientific article published on 11 January 2011

Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation

scientific article published on 07 September 2009

Mutations and prognosis in primary myelofibrosis

scientific article published on 26 April 2013

Mutations in the XPC gene in families with xeroderma pigmentosum and consequences at the cell, protein, and transcript levels

scientific article published in April 2000

Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning

scientific article published on 01 January 2020

PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia

scientific article published on 01 May 2005

Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia.

scientific article

Platelet count predicts driver mutations' co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis

scientific article published on 13 October 2020

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.

scientific article

Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.

scientific article published on 11 September 2008

Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.

scientific article

Rap2, but not Rap1 GTPase is expressed in human red blood cells and is involved in vesiculation

scientific article

Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders-A consensus project of the Italian Society of Hematology

scientific article

Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS ⬇️

scientific article published on September 30, 2010

Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

scientific article

Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms

scientific article published on 01 May 2019

SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts

scientific article published on 8 May 2015

Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms

scientific article

Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders

scientific article published on 5 November 2007

Somatic mutations of calreticulin in myeloproliferative neoplasms

scientific article

The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera

scientific article

The JAK2 V617F mutation in patients with cerebral venous thrombosis

scientific article

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients

scientific article published on 19 February 2014

The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms ⬇️

scientific article published on December 20, 2010

Validation of cytogenetic-based risk stratification in primary myelofibrosis.

scientific article published in April 2010

Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.

scientific article published on 5 April 2018

Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms

scientific article published on 30 September 2015

miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis

scientific article

List of works by Daniela Pietra

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.

A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis

A novel germline JAK2 mutation in familial myeloproliferative neoplasms.

A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications

Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms

Allelic imbalance in CALR somatic mutagenesis

Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2.

Blast phase of essential thrombocythemia: A single center study

Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis.

Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations

CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis

CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles

COLD-PCR and Innovative Microarray Substrates for Detecting and Genotyping MPL Exon 10 W515 Substitutions

Cerebral venous thrombosis and myeloproliferative neoplasms: Results from two large databases

Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes

Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm

Clinical significance of genetic aberrations in secondary acute myeloid leukemia

Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders

Clinical significance of somatic mutation in unexplained blood cytopenia

Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms

Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2.

Concordance of assays designed for the quantification of JAK2V617F: a multicenter study

Cord blood in vitro expanded CD41 cells: identification of novel components of megakaryocytopoiesis

Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms.

Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms

Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

Diagnosis and management of prefibrotic myelofibrosis

Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.

Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients.

Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia

Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene

Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group

Familial Chronic Myeloproliferative Disorders: Clinical Phenotype and Evidence of Disease Anticipation

Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome

Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project

Genetic and clinical heterogeneity of ferroportin disease

Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression

Germline RBBP6 mutations in familial myeloproliferative neoplasms.

Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm

Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia

Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients.

Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation

Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosis.

JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders

JAK2 (V617F) mutation in healthy individuals

JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms.

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

LNK mutations in familial myeloproliferative neoplasms.

Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes

Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis

Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations

Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation

Mutations and prognosis in primary myelofibrosis

Mutations in the XPC gene in families with xeroderma pigmentosum and consequences at the cell, protein, and transcript levels

Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning

PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia

Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia.

Platelet count predicts driver mutations' co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.

Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.

Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.

Rap2, but not Rap1 GTPase is expressed in human red blood cells and is involved in vesiculation

Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders-A consensus project of the Italian Society of Hematology

Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS ⬇️

Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms

SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts

Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms

Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders

Somatic mutations of calreticulin in myeloproliferative neoplasms

The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera

The JAK2 V617F mutation in patients with cerebral venous thrombosis

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients

The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms ⬇️

Validation of cytogenetic-based risk stratification in primary myelofibrosis.